Drugs & TargetsFree FDA approves Revlimid as maintenance in multiple myeloma following transplant February 24, 2017Vol.43 No.08
Drugs & TargetsFree Zykadia receives a Priority Review for frontline use in ALK+ metastatic NSCLC February 24, 2017Vol.43 No.08
Drugs & TargetsFree FDA accepts Mylan’s BLA for biosimilar pegfilgrastim February 24, 2017Vol.43 No.08
Drugs & TargetsFree MIODx licenses immunotherapy technologies from UCSF February 24, 2017Vol.43 No.08
FreeIn Brief Jeffrey Patrick new director of Ohio State Drug Development Institute February 24, 2017Vol.43 No.08
Free Moonshot funds are not a substitute for sustained NCI funding, Lowy warns as prospect of year-long continuing resolution looms February 24, 2017Vol.43 No.08
Conversation with The Cancer LetterFree Marcia Crosse: This “failure of the adverse event reporting system” should serve as a “wake up call” February 24, 2017Vol.43 No.08By Matthew Bin Han Ong
Free GAO: Power morcellation is a unique case study in patient harmHundreds died over two decades as reporting requirements were ignored. February 24, 2017Vol.43 No.08By Matthew Bin Han Ong
Free MMRF contributes largest disease-specific cancer genome dataset to NCI’s Genomic Data Commons February 10, 2017Vol.43 No.06By Matthew Bin Han Ong
